Arbutus Biopharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Lindsay Androski
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Arbutus Biopharma: A Wing And A Prayer
Mar 28Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
Jan 30Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Jan 07Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17CEO
Lindsay Androski (47 yo)
less than a year
Tenure
Ms. Lindsay Androski, JD, MBA, is Interim President, CEO & Director of Arbutus Biopharma Corporation from February 25, 2025 and also serves as its Chairman since February 2025. serves as an Independent Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Vice President of Investor Relations | 3.7yrs | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Corporate Secretary | 15yrs | no data | no data |
2.0yrs
Average Tenure
48yo
Average Age
Experienced Management: ABUS's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data |
0.3yrs
Average Tenure
49yo
Average Age
Experienced Board: ABUS's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 11:00 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arbutus Biopharma Corporation is covered by 26 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Madhu Kumar | Baird |
| David Martin | Bloom Burton & Co. |